Topic:

Venture Capital

Latest Headlines

Latest Headlines

Mapi Pharma closes $10M Series A round after two scuttled IPOs

Mapi Pharma has closed a $10 million (€9 million) Series A round to finance mid-phase trials of its once-a-month version of Teva's blockbuster multiple sclerosis drug, Copaxone. The round follows two aborted attempts to raise cash in a Nasdaq IPO.

A well-connected Pronutria revs up amino acid research with $39M C round

Cambridge, MA-based Pronutria, a graduate of Flagship's VentureLabs that recently attracted some high-profile R&D talent, has put the finishing touches to a $39 million C round designed to advance a pipeline of therapeutic-strength amino acid drugs in the clinic.

HIV biotech Calimmune bags $15M to move one-time gene therapy into new trials

After getting started 9 years ago with backing from angel investors, Calimmune just landed a $15 million B round, positioning the biotech to move into the clinic with a gene therapy designed to durably stymie the lethal HIV with one treatment.

Can PureTech and its high-profile board raise $160M in London?

Boston-based PureTech, an investment group which is better known for its high-profile board than its portfolio of upstart life sciences companies, has landed in the U.K. with a plan to raise $160 million on the London stock market.

Abivax files for IPO to finance trials of HepB vaccine, HIV antiviral

Abivax has filed the paperwork for an IPO in Paris. The listing is intended to give Abivax the cash to fund mid- to late-phase trials of its two lead candidates, a therapeutic vaccine against hepatitis B and a small-molecule inhibitor of HIV replication.

BioInvent, BiondVax pocket $9.5M each in separate stock sales

BioInvent and BiondVax Pharmaceuticals have wrapped up their respective fundraising initiatives. Sweden's BioInvent pulled in $9.5 million to fuel the advance of its oncology pipeline, while Israel's BiondVax bagged a similar amount to continue work on its universal flu vaccine.

PsiOxus bags $39M from Woodford, GSK for checkpoint inhibitor combo trial

Neil Woodford's new $1.2 billion fund and GlaxoSmithKline's VC unit have contributed to a $39 million Series C round in PsiOxus Therapeutics. The cash will allow PsiOxus to test its oncolytic virus together with a checkpoint inhibitor, a combination it thinks can make the immuno-oncology treatment effective against otherwise resistant targets.

Galapagos inflates IPO again as AbbVie, J&J jockey for position

Galapagos has ratcheted up its IPO expectations for the second time in a week. The latest maximum offering is just shy of $290 million (€258 million), one-fifth of which is expected to come from potential suitors AbbVie and Johnson & Johnson.

Surge in overseas investment drives Israel to life sci fundraising record

Israel has joined the list of countries that obliterated their life science fundraising records in 2014. Data from IVC Research Center show Israeli life science companies pulled in $801 million (€708 million) last year, a 55% jump on the previous high that was underpinned by foreign investors opening their checkbooks with unprecedented regularity.

EU's investment bank continues move into R&D financing with €50M Bavarian Nordic loan

Bavarian Nordic is the latest company to benefit from the European Investment Bank's newfound willingness to finance drug development, snagging access to up to €50 million ($56 million) in loans for its Ebola and immunotherapy programs.